Brad R Henke1, Steven M Sparks
1Metabolic and Viral Diseases Drug Discovery, GlaxoSmithKline, P.O. Box 13398, Research Triangle Park, NC 27705, USA. Brad.R.Henke@gsk.com
Small molecule inhibitors targeting glycogen phosphorylase, an enzyme crucial for glucose release, show promise for treating Type 2 diabetes by lowering high blood sugar levels.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: